![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Celgene Corporation |
---|---|
Information provided by: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT00072722 |
Phase II randomized open-label, two-arm study of safety and efficacy of CC-4047 in subjects with metastatic hormone refractory prostate cancer (HRPC)
Condition | Intervention | Phase |
---|---|---|
Prostate Cancer |
Drug: CC-4047 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Phase II Randomized Open-Label, Two-Arm Study of Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Colorado | |
University of Colorado Health Science Center | |
Denver, Colorado, United States, 80220-3706 | |
United States, Texas | |
Baylor College of Medicine | |
Houston, Texas, United States, 77030 |
Study ID Numbers: | CC-4047-PC-002 |
Study First Received: | November 7, 2003 |
Last Updated: | December 18, 2006 |
ClinicalTrials.gov Identifier: | NCT00072722 |
Health Authority: | United States: Food and Drug Administration |
Prostate Cancer Metastatic Hormone Refractory Prostate Cancer CC4047 |
CC-4047 Prostate Carcinoma Celgene |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms |
Genital Diseases, Male Prostatic Neoplasms Carcinoma |
Neoplasms Neoplasms by Site |